Novel polyamine derivatives
AssigneeNihon University
InventorsMuneharu Miyake, Tadashi Kusama, Takashi Masuko
Life of this patent
Estimating the term…
Abstract
A compound having the general formula (I) or a pharmacologically acceptable salt thereof: X—NH—Y—NH—R1 (I) [wherein X represents R2—SO2— in which R2 represents an optionally substituted lower alkyl group or phenyl group; Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11— and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group; and R1 represents hydrogen or an optionally substituted lower alkyl group, with the proviso that the case where X represents a tosyl group, Y represents —(CH2)3—NH—(CH2)4—NH—(CH2)3— and R1 represents hydrogen is excepted].
Claims8
A compound having the general formula (I) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (I)
- [wherein
- X represents a tosyl group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11— and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- R1 represents a hydrogen atom or an optionally substituted lower alkyl group or NH—R1 represents a guanidyl group, with the proviso that the case where Y represents —(CH2)3—NH—(CH2)4—NH—(CH2)3— and R1 represents hydrogen atom is excepted].
A compound having the general formula (I) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (I)
- wherein
- X represents an optionally substituted lower alkyl-SO2— group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11—, and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- NH—R1 represents a guanidyl group.
An N-methyl-D-aspartate receptor activity inhibitor comprising a compound having the general formula (II) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (II)
- [wherein
- X represents a tosyl group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11— and —R12—NH—R13—NH—R14—NH—R15—, in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- R1 represents a hydrogen atom or an optionally substituted lower alkyl group or NH—R1 represents a guanidyl group, with the proviso that the case where Y represents —(CH2)3—NH—(CH2)4—NH—(CH2)3— and R1 represents hydrogen atom is excepted].
An N-methyl-D-aspartate receptor activity inhibitor comprising a compound having the general formula (II) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (II)
- [wherein
- X represents an optionally substituted lower alkyl-SO2— group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11, and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- NH—R1 represents a guanidyl group].
A prophylactic or therapeutic drug for Alzheimer's disease or Parkinson's disease, comprising a compound having the general formula (II) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (II)
- wherein
- X represents a tosyl group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11— and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- R1 represents a hydrogen atom or an optionally substituted lower alkyl group or NH—R1 represents a guanidyl group,
- with the proviso that the case where Y represents —(CH2)3—NH—(CH2)4—NH—(CH2)3— and R1 represents hydrogen atom is excepted.
A prophylactic or therapeutic drug for Alzheimer's disease or Parkinson's disease, comprising a compound having the general formula (II) or a pharmacologically acceptable salt thereof:
- X—NH—Y—NH—R1 (II)
- wherein
- X represents an optionally substituted lower alkyl-SO2— group;
- Y represents a group selected from the group consisting of —R3—NH—R4—, —R5—NH—R6—NH—R7—, —R8—NH—R9—NH—R10—NH—R11—, and —R12—NH—R13—NH—R14—NH—R15— in which R3 to R15 each independently represent a C3 to C5 alkylene group;
- and
- NH—R1 represents a guanidyl group.
Dependencies are inferred from the claim text.